Strontium ranelate - a promising therapeutic principle in osteoporosis

Journal of Trace Elements in Medicine and Biology

Volumn 26, Issue 2-3, 2012, Pages 153-156

  Boivin, Georges ^a,b   Doublier, Audrey ^a,b   Farlay, Delphine ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ DE LYON   (France)

Author keywords

Bone quality; Postmenopausal osteoporosis; Quantitative microradiography; Strontium ranelate; X ray microanalysis

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; STRONTIUM RANELATE;

ARTICLE; BONE DENSITY; BONE MINERALIZATION; BONE TISSUE; DRUG EFFICACY; DRUG SAFETY; FRAGILITY FRACTURE; HIP FRACTURE; HUMAN; NONHUMAN; OSSIFICATION; OSTEOLYSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RISK REDUCTION; VERTEBRA FRACTURE;

BONE DENSITY CONSERVATION AGENTS; FEMALE; HUMANS; ORGANOMETALLIC COMPOUNDS; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; THIOPHENES;

EID: 84862555339     PISSN: 0946672X     EISSN: 18783252     Source Type: Journal    
DOI: 10.1016/j.jtemb.2012.03.013     Document Type: Article

References (48)

1. Bonnelye E., Chabadel A., Saltel F., Jurdic P. Dual effect of strontium ranelate: stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro. Bone 2008, 42:129-138.
2. Canalis E., Hott M., Deloffre P., Tsouderos Y., Marie P.J. The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro. Bone 1996, 18:517-523.
3. Takahashi N., Sasaki T., Tsouderos Y., Suda T. S 12911-2 inhibits osteoclastic bone resorption in vitro. J Bone Miner Res 2003, 18:1082-1087.
4. Barbara A., Delannoy P., Denis B.G., Marie P.J. Normal matrix mineralization induced by strontium ranelate in MC3T3-E1 osteogenic cells. Metabolism 2004, 53:532-537.
5. Baron R., Tsouderos Y. In vitro effects of S12911-2 on osteoclast function and bone marrow macrophage differentiation. Eur J Pharmacol 2002, 450:11-17.
6. Buehler J., Chappuis P., Saffar J.L., Tsouderos Y., Vignery A. Strontium ranelate inhibits bone resorption while maintaining bone formation in alveolar bone in monkeys (Macaca fascicularis). Bone 2001, 29:176-179.
7. Delannoy P., Bazot D., Marie P.J. Long-term treatment with strontium ranelate increases vertebral bone mass without deleterious effect in mice. Metabolism 2002, 51:906-911.
8. Hott M., Deloffre P., Tsouderos Y., Marie P.J. S12911-2 reduces bone loss induced by short-term immobilization in rats. Bone 2003, 33:115-123.
9. Marie P.J., Hott M., Modrowski D., De Pollak C., Guillemain J., Deloffre P., et al. An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats. J Bone Miner Res 1993, 8:607-615.
10. Ammann P., Shen V., Robin B., Mauras Y., Bonjour J.P., Rizzoli R. Strontium ranelate improves bone resistance by increasing bone mass and improving architecture in intact female rats. J Bone Miner Res 2004, 19:2012-2020.
11. Ammann P., Badoud I., Barraud S., Dayer R., Rizzoli R. Strontium ranelate treatment improves trabecular and cortical intrinsic bone tissue quality, a determinant of bone strength. J Bone Miner Res 2007, 22:1419-1425.
12. Bain S.D., Jerome C., Shen V., Dupin-Roger I., Ammann P. Strontium ranelate improves bone strength in ovariectomized rat by positively influencing bone resistance determinants. Osteoporos Int 2009, 20:1417-1428.
13. Marie P.J., Felsenberg D., Brandi M.L. How strontium ranelate, via opposite effects on bone resorption and formation, prevents osteoporosis. Osteoporos Int 2011, 22:1659-1667.
14. Meunier P.J., Roux C., Ortolani S., Diaz-Curiel M., Compston J., Marquis P., et al. Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis. Osteoporos Int 2009, 20:1663-1673.
15. Meunier P.J., Roux C., Seeman E., Ortolani S., Badurski J.E., Spector T.D., et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004, 350:459-468.
16. Meunier P.J., Slosman D.O., Delmas P.D., Sebert J.L., Brandi M.L., Albanese C., et al. Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis - a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab 2002, 87:2060-2066.
17. Reginster J.Y., Bruyere O., Sawicki A., Roces-Varela A., Fardellone P., Roberts A., et al. Long-term treatment of postmenopausal osteoporosis with strontium ranelate: results at 8 years. Bone 2009, 45:1059-1064.
18. Reginster J.Y., Seeman E., De Vernejoul M.C., Adami S., Compston J., Phenekos C., et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: treatment of peripheral osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005, 90:2816-2822.
19. Arlot M.E., Jiang Y., Genant H.K., Zhao J., Burt-Pichat B., Roux J.P., et al. Histomorphometric and microCT analysis of bone biopsies from postmenopausal osteoporotic women treated with strontium ranelate. J Bone Miner Res 2008, 23:215-222.
20. Hamdy N.A. Strontium ranelate improves bone microarchitecture in osteoporosis. Rheumatology (Oxford) 2009, 48(suppl 4):9-13.
21. Rizzoli R., Laroche M., Krieg M.A., Frieling I., Thomas T., Delmas P., et al. Strontium ranelate and alendronate have differing effects on distal tibia bone microstructure in women with osteoporosis. Rheumatol Int 2010, 30:1341-1348.
22. Seeman E., Delmas P.D. Bone quality - the material and structural basis of bone strength and fragility. N Engl J Med 2006, 354:2250-2261.
23. Boivin G., Meunier P.J. The degree of mineralization of bone tissue measured by computerized quantitative contact microradiography. Calcif Tissue Int 2002, 70:503-511.
24. Boivin G., Meunier P.J. Methodological considerations in measurement of bone mineral content. Osteoporos Int 2003, 14(suppl 5):22-28.
25. Nuzzo S., Peyrin F., Cloetens P., Bachurel J., Boivin G. Quantification of the degree of mineralization of bone in three dimension using synchrotron radiation microtomography. Med Phys 2002, 29:2672-2681.
26. Glimcher M.J. The nature of the mineral phase in bone. Metabolic bone disease 1998, Academic Press, San Diego, pp. 23-50. M.J. Glimcher (Ed.).
27. Boivin G., Bala Y., Doublier A., Farlay D., Ste-Marie L.G., Meunier P.J., et al. The role of mineralization and organic matrix in the microhardness of bone tissue from controls and osteoporotic patients. Bone 2008, 43:532-538.
28. Farlay D., Panczer G., Rey C., Delmas P.D., Boivin G. Mineral maturity and crystallinity index are distinct characteristics of bone mineral. J Bone Miner Metab 2010, 28:433-445.
29. Bala Y., Farlay D., Simi C., Meunier P.J., Delmas P.D., Boivin G. Time sequence of secondary mineralization and microhardness of bone in an ewe model. Bone 2010, 46:1204-1212.
30. Currey J.D. The effect of strain rate, reconstruction and mineral content on some mechanical properties of bovine bone. J Biomech 1975, 8:81-86.
31. Follet H., Boivin G., Rumelhart C., Meunier P.J. The degree of mineralization is a determinant of bone strength. A study on human calcaneus. Bone 2004, 34:783-789.
32. Bala Y., Depalle B., Douillard T., Meille S., Clement P., Follet H., et al. Respective roles of organic and mineral components of human cortical bone matrix in micromechanical behavior: an instrumented indentation study. J Mech Behav Biomed Mater 2011, 4:1473-1482.
33. Misof B.M., Roschger P., Cosman F., Kurland E., Tesch W., Messmer P., et al. Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment. J Clin Endocrinol Metab 2003, 88:1150-1156.
34. Arlot M., Meunier P.J., Boivin G., Haddock L., Tamayo J., Correa-Rotter R., et al. Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J Bone Miner Res 2005, 20:1244-1253.
35. Boivin G.Y., Chavassieux P.M., Santora A.C., Yates J., Meunier P.J. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 2000, 27:687-694.
36. Boivin G., Lips P., Ott S.M., Harper K.D., Sarkar S., Pinette K.V., et al. Contribution of raloxifene and calcium and vitamin D3 supplementation to the increase of the degree of mineralization of bone in postmenopausal women. J Clin Endocrinol Metab 2003, 88:4199-4205.
37. Boivin G., Vedi S., Purdie D.W., Compston J.E., Meunier P.J. Influence of conventional and high doses of estrogen on the degree of mineralisation of bone tissue: a quantitative microradiographic analysis in postmenopausal women. Bone 2005, 36:562-567.
38. Borah B., Ritman E.L., Dufresne T.E., Jorgensen S.M., Liu S., Sacha J., et al. The effects of risedronate on bone mineralization as measured by micro-computed tomography with synchrotron radiation: correlation to histomorphometric indices of turnover. Bone 2005, 37:1-9.
39. Bala Y., Farlay D., Chapurlat R., Boivin G. Modifications of bone material properties in postmenopausal osteoporotic women long-term treated with alendronate. Eur J Endocrinol 2011, 165:647-655.
40. Bala Y., Depalle B., Farlay D., Douillard T., Meille S., Follet H., et al. Bone micromechanical properties are compromised during long-term alendronate therapy independently of mineralization. J Bone Miner Res 2012, 27:825-834.
41. Marie P.J., Ammann P., Boivin G., Rey C. Mechanisms of action and therapeutic potential of strontium in bone. Calcif Tissue Int 2001, 69:121-129.
42. Boivin G., Deloffre P., Perrat B., Panczer G., Boudeulle M., Mauras Y., et al. Strontium distribution and interactions with bone mineral in monkey iliac bone after strontium salt (S 12911) administration. J Bone Miner Res 1996, 11:1302-1311.
43. Farlay D., Boivin G., Panczer G., Lalande A., Meunier P.J. Long-term strontium ranelate administration in monkeys preserves characteristics of bone mineral crystals and degree of mineralization of bone. J Bone Miner Res 2005, 20:1569-1578.
44. Boivin G., Farlay D., Simi C., Meunier P.J. In osteoporotic women treated with strontium ranelate, strontium is located in bone formed during treatment with a maintained degree of mineralization. Osteoporos Int 2010, 21:667-677.
45. Arlot M.E., Jiang Y., Genant H.K., Zhao J., Burt-Pichat B., Roux J.P., et al. Histomorphometric and μ-CT analysis of bone biopsies from postmenopausal osteoporotic women treated with strontium ranelate. J Bone Miner Res 2008, 23:215-222.
46. Ammann P., Badoud I., Barraud S., Dayer R., Rizzoli R. Strontium ranelate treatment improves trabecular and cortical intrinsic bone tissue quality, a determinant of bone strength. J Bone Miner Res 2007, 23:1419-1425.
47. Li C., Paris O., Siegel S., Roschger P., Paschalis E.P., Klaushofer K., et al. Strontium is incorporated into mineral crystals only in newly formed bone during strontium ranelate treatment. J Bone Miner Res 2010, 25:968-975.
48. Doublier A., Farlay D., Khebbab M.T., Jaurand X., Meunier P.J., Boivin G. Distribution of strontium and mineralization in iliac bone biopsies from osteoporotic women long-term treated with strontium ranelate. Eur J Endocrinol 2011, 165:469-476.